Latest Bevacizumab Stories

American Health Assistance Foundation Calls for Greater Investment in Research to Halt Eye Disease This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology. Researchers found that two drugs known as Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat the wet form of AMD, were similarly effective in maintaining...

Year 2 results corroborate initial findings that 2 medications provide strikingly similar results Two drugs commonly used to treat age-related macular degeneration (AMD) yield similar improvements in vision for patients receiving treatments on a monthly or as-needed basis, according to a study from researchers at the Center for Preventive Ophthalmology and Biostatistics (CPOB) at the Perelman School of Medicine at the University of Pennsylvania. The year-two results of the Comparison of...

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health. Of the two drugs, Avastin is most frequently used to treat AMD. However, prior to the...

Tokyo, Apr 23, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the German Federal Joint Committee (G-BA)(1), the supreme decision-making body for the self-governing medical system in Germany, considers the use of Halaven(R) (eribulin mesylate) to have additional benefit versus comparative treatments, defined by the G-BA for women who have already had extensive prior treatment for metastatic or locally advanced breast cancer. This assessment by the...

BOULDER, Colo., April 20, 2012 /PRNewswire/ -- Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib. Results showed that the VeriStrat test was able to identify patients likely to...

Connie K. Ho for RedOrbit.com On Tuesday, April 17, researchers from the University of California, San Francisco (UCSF) presented results at the American Association of Neurological Surgeons (AANS) meeting in Miami, Florida that a new brain cancer vaccine tailored to individual subjects had been successful in its second clinical trial. The vaccine is for patients who suffer from recurrent glioblastoma multiforme, a type of cancer, and it has helped extend patients’ lives. The trial...

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found. The study is being published in the April 18 Journal of the American Medical Association, a these issue on comparative effectiveness research....

PLANO, Texas, April 11, 2012 /PRNewswire/ -- MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA. MC-1101 is a proprietary, topically administered...

A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that was previously demonstrated at 12 months was maintained through 24 months, according to a report published Online First by Archives of Ophthalmology, a JAMA Network publication. Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT) has...

Another batch of counterfeit Avastin, a cancer fighting drug, has been discovered in the United States. The new batch of counterfeit drugs discovered in the US was purchased in Turkey and shipped through Britain, officials said on Wednesday. Though the business in between Turkey and the US is different this time around, this shipping pattern closely resembles an earlier episode. The fake version of the Roche Genentech drug was first discovered in February and was received by as many as 19...